Pharma Companies and Regulators

This chapter discusses the reception of the speaker's idea by pharma companies and regulators. It highlights the need for a radical realignment of these entities for implementation. It also explores the challenges of integrating AI workflows into clinical trial processes and the potential impact on drug development.